Our purpose is to help people with cancer and rare diseases live longer, better quality lives.
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic (‘theranostic’) products using molecularly targeted radiation (MTR). Telix’s research pipeline aims to address significant unmet medical need in prostate, kidney, brain (glioblastoma), and hematologic cancers as well as a range of immunologic and rare diseases. We are also keenly interested in partnership and in-licensing opportunities to further expand our portfolio. Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States. In 2020, Telix acquired a production facility in Seneffe, Belgium, with one of the broadest private sector medical isotope licences in Europe. This delivers significant operational flexibility, and ensures the ability to meet commercial production requirements in Europe.
